Project: Targeted alpha therapy in the treatment of ovarian cancer
| Acronym | TAT-OV-ASTATINE-2 (Reference Number: 11435) |
| Duration | 01/09/2017 |
| Project Topic | The idea of this project is to develop a targeted alpha-particle radio-immunotherapy (TAT) based on astatine conjugated to the monoclonal antibody (MAb) farletuzumab as a new drug for the treatment of ovarian cancer. We will conduct the First-in-Man clinical trial in patients in complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma. The aim is to study pharmacokinetics (PK) and particularly bio-distribution; as well as safety and toxicity. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 7 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Smerud Medical Research International AS | Coordinator | Norway |
| 2 | Sahlgrenska University Hospital | Partner | Sweden |